TREM2 Expression in Schizophrenia by Mori, Yoko et al.
RESEARCH ARTICLE
TREM2mRNA Expression in Leukocytes Is
Increased in Alzheimer’s Disease and
Schizophrenia
Yoko Mori1*, Yuta Yoshino1, Shinichiro Ochi1, Kiyohiro Yamazaki1, Kentaro Kawabe1,
Masao Abe1, Tomoji Kitano1, Yuki Ozaki1, Taku Yoshida1, Shusuke Numata2,
Takaaki Mori1, Junichi Iga1, Norio Kuroda3, Tetsuro Ohmori2, Shu-ichi Ueno1
1 Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine,
Toon, Ehime, Japan, 2 Department of Psychiatry, Course of Integrated Brain Sciences, Medical Informatics,
Institute of Health Biosciences, The University of Tokushima Graduate School, Kuramoto-cho, Tokushima,
Japan, 3 Kuroda Hospital, Masaki-cho, Ehime, Japan
* yoko-m@m.ehime-u.ac.jp
Abstract
TREM2 and TYROBP are causal genes for Nasu–Hakola disease (NHD), a rare autosomal
recessive disease characterized by bone lesions and early-onset progressive dementia.
TREM2 forms a receptor signaling complex with TYROBP, which triggers the activation of
immune responses in macrophages and dendritic cells, and the functional polymorphism of
TREM2 is reported to be associated with neurodegenerative disorders such as Alzheimer’s
disease (AD). The objective of this study was to reveal the involvement of TYROBP and
TREM2 in the pathophysiology of AD and schizophrenia.Methods: We investigated the
mRNA expression level of the 2 genes in leukocytes of 26 patients with AD and 24 with
schizophrenia in comparison with age-matched controls. Moreover, we performed gene
association analysis between these 2 genes and schizophrenia. Results: No differences
were found in TYROBPmRNA expression in patients with AD and schizophrenia; however,
TREM2mRNA expression was increased in patients with AD and schizophrenia compared
with controls (P < 0.001). There were no genetic associations of either gene with schizo-
phrenia in Japanese patients. Conclusion: TREM2 expression in leukocytes is elevated not
only in AD but also in schizophrenia. Inflammatory processes involving TREM2may occur
in schizophrenia, as observed in neurocognitive disorders such as AD. TREM2 expression
in leukocytes may be a novel biomarker for neurological and psychiatric disorders.
Introduction
Nasu–Hakola disease (NHD), also called polycystic lipomembranous osteodysplasia with scle-
rosing leukoencephalopathy (PLOSL), is an extremely rare autosomal recessive disease charac-
terized by bone lesions and early-onset progressive neurocognitive disorders [1]. NHD is
caused by mutations in the triggering receptor expressed on myeloid cell 2 (TREM2) on
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chromosome 6p21.1 or TYRO protein tyrosine kinase binding protein (TYROBP) on chromo-
some 19q13.1 [2]. These genes encode different domains of the same receptor signaling protein
in the activation of immune response, called the TREM2/TYROBP signaling cascade. Several
studies have shown that TREM2/TYROBP signaling is essential for the development of osteo-
clasts and dendritic cells under homeostatic conditions [3] and that synaptogenesis is deregu-
lated in TYROBP-deficient mice [4, 5]. However, the absence of immunological derangement
in NHD remains enigmatic.
TREM2 is also known to be associated with Alzheimer’s disease (AD) and other neurode-
generative diseases. A functional single nucleotide polymorphism (SNP) in TREM2
(rs75932628>T, p.R47H) is associated with AD [6], Parkinson’s disease [7], frontotemporal
dementia [8], and amyotrophic lateral sclerosis [9]. Moreover, Lue et al. [10] reported that
TREM2 expression is upregulated in the brain of patients with AD. Although a vast amount of
clinical data has strongly implicated the role of inflammatory and degenerative processes in the
pathophysiology of schizophrenia, TREM2 expression in schizophrenia has not yet been exam-
ined. In the present study, we report gene expression and association analyses of both TYROBP
and TREM2 in patients with AD and schizophrenia.
Methods
Subjects
Descriptive data for each group of participants are shown in Table 1. All participants in this
study were of Japanese origin and unrelated to each other.
Participants in AD analysis. We recruited 26 patients with AD [8 males and 18 females,
mean age ± standard deviation (SD) = 79.6 ± 4.0 years] from Ehime University Hospital and
related community hospitals. AD was diagnosed according to criteria established by the
National Institute on Aging and the Alzheimer’s Association and classified as probable AD
dementia [11] with bilateral hippocampal atrophy using brain CT or brain MRI findings. Sub-
jects were also assessed by the Mini Mental State Examination (MMSE) [12] and Clinical
Table 1. Demographic data and clinical characteristics of each group.
A. Expression analysis for Alzheimer’s disease.
Alzheimer's disease (n = 26) AD-cnt (n = 26) P-value
sex (male: female) 8:18 13:13 0.26
age(years mean ± SD) 79.6 ± 4.0 77.5 ± 4.1 0.07
MMSE score (points mean ± SD) 18.0 ± 5.6 29.7 ± 0.6 < 0.001
CDR number of each grade (0: 0.5: 1: 2: 3) 0: 1: 8: 14: 3 26: 0: 0: 0: 0 < 0.001
B. Expression analysis for schizophrenia.
schizophrenia (n = 24) Sc-cnt (n = 24) P-value
Sex (male: female) 7:17 7:17 1
age(years mean ± SD) 54.8 ± 18.0 54.8 ± 18.0 1
disease duration (years mean ± SD) 24.2 ± 14.7 none ―
C. Genotyping analysis.
schizophrenia (n = 796) control (n = 510) P-value
sex (male: female) 457: 339 265: 245 0.06
age(years mean ± SD) 53.0 ± 14.4 35.1 ± 14.2 < 0.001
AD-cnt, the controls against Alzheimer’s disease in expression analysis; MMSE, Mini Mental State Examination; CDR, Clinical Dementia Rating. The
score of 0–3 shows classification of dementia (0 = none, 0.5 = questionable, 1 = mild, 2 = moderate, 3 = severe); Sc-cnt, the controls against
schizophrenia in expression analysis. The p-value was calculated by student T test, Chi-squired test, and Fisher’s exact test.
doi:10.1371/journal.pone.0136835.t001
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Dementia Rating (CDR) [13]. The AD control group (AD-cnt) included 22 age-matched
elderly participants with normal cognitive function (13 males and 13 females, mean
age ± SD = 77.5 ± 4.1 years) who agreed to participate in this study. For inclusion, subjects had
to be capable of living independently, have MMSE scores over 28, and be free of cognitive
impairment or morphological brain abnormality.
Participants in schizophrenia analysis. We recruited 24 patients with schizophrenia
(7 males and 17 females, mean age ± SD = 54.8 ± 18.0 years, disease duration at blood
draw = 24.2 ± 14.7 years) as well as 24 age-matched controls (Sc-cnt; 7 males and 17 females,
mean age ± SD = 54.8 ± 18.0 years) from Ehime University Hospital and related community
hospitals. In addition, we enrolled 796 patients with schizophrenia (457 males, 339 females,
age = 53.0 ± 3.4 years, 34 patients did not indicate age) who visited Ehime or Tokushima Uni-
versity Hospitals for a gene association study. Schizophrenia was diagnosed according to the
Diagnostic and Statistical Manual of Mental Disorders IV criteria by at least 2 certified psychia-
trists on the basis of clinical interviews and review of medical records. The comparison group
included 510 healthy volunteers (265 males, 245 females, mean age ± SD = 35.1 ± 14.2 years)
without psychiatric signs, psychiatric family history, or past history of mental disorders.
NHD participant. A 42-year-old male NHD patient homozygous for a TYROBPmutation
(TYROBP c.141delG;manuscript in preparation) was included as a reference. We obtained his
RNA twice, at intervals of 30 months, and confirmed that both samples expressed equivalent
levels of TYROBP. We also analyzed his father and mother (aged 72 and 68 years, respectively),
both of whom were heterozygous for the TYROBP c.141delG mutation.
Ethical issues
All procedures followed were in accordance with the ethical standards of the responsible com-
mittee on human experimentation (institutional and national) and with the Helsinki Declara-
tion of 1964 and later revision. This study was approved by the institutional ethics committees
of The Ethics Review Committee for Human Genome/Gene Analysis Research in Ehime Uni-
versity Graduate School of Medicine and the University of Tokushima Graduate School as
“Genetic Studies on Neuropsychiatric Diseases” (registry number; 25-K4), and written
informed consent was confirmed by all participants or their guardians before the acquisition of
blood samples.
Blood sample collection
Whole peripheral blood samples were collected for the extraction of total RNA and genomic
DNA, according to the standard protocol, in PaxGene Blood RNA Systems tubes (BD, Tokyo,
Japan) and potassium EDTA tubes, respectively. Absorption spectrophotometry, using Nano-
Drop-1000 (Thermo Fisher scientific, Yokohama, Japan), was used to determine RNA concen-
trations and purity (260/280 ratio above 1.8 was used). RNA (1 μg per sample) was reverse-
transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
CA, USA), in a total reaction volume of 40 μL. Genomic DNA was isolated from whole blood
leukocytes using the QIAamp DNA Blood Mini Kit (Qiagen, Tokyo, Japan), according to the
manufacturer’s protocol.
Expression analyses
For a quantitative estimate of TYROBP and TREM2mRNA levels, the StepOnePlus Real-Time
PCR System (Applied Biosystems) was used. Specific TaqMan probes were employed (Assay
ID: TYROBP; Hs00182426_m1, TREM2; Hs00219132_m1), and the relative expression level of
TYROBP or TREM2mRNA was determined by comparison with the housekeeping gene
TREM2 Expression in Schizophrenia
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GAPDH [14–16], serving as an internal standard (all Taqman probes from Applied Biosys-
tems). The final volume reaction was 10 μL using the TaqMan Universal Master Mix (Applied
Biosystems). Relative mRNA levels were calculated via the 2−ΔΔCT method [17] using StepOne
software (Applied Biosystems). We averaged the fold changes from three wells for each sample
(triplicate) and used this average value for statistical analyses. The NHD patient was used for
calibration in all experiments to correct the observational error.
SNP analysis
Three SNPs, rs8113524 (NG_009304.1; assay ID: C___2604899_10), rs3817624 (NG_
009304.1; assay ID: C__25603557_20), and rs2234256 (NG_011561.1; assay ID: C__
15948232_10) (Table 2) were selected using HaploView v4.2 (Cambridge, MA) as tag SNPs,
with squared correlation coefficient (r2) between 2 SNPs> 0.8 and minor allele frequency
(MAF)> 0.01, on the basis of the current International HapMap project database (http://
hapmap.ncbi.nlm.nih.gov/index.html.en). These were analyzed for association study with
schizophrenia. Additional SNPs, rs429358 (NG_007084.2; assay ID: C___3084793_20) and
rs7412 (NG_007084.2; assay ID: C____904973_10) were used to determine apolipoprotein E
(APOE) isoforms using a real-time SNP genotyping system (TaqMan Assays, Applied Biosys-
tems). Following this, 1× TaqMan PCRMaster Mix, 1× TaqMan SNP genotyping assay, 10 ng
genomic DNA, and ultrapure water to a final reaction volume of 6 μL were mixed in each well
of an optical plate. Allelic discrimination was performed using StepOnePlus and analyzed
using its software.
Statistics
Statistical analyses were performed using SPSS v22 (IBM, Tokyo, Japan). Expression levels of
TYROBP and TREM2 were compared using the Mann–Whitney U-test and Student’s t-test.
Correlations of gene expression with age, disease duration, and MMSE score were analyzed
using the Spearman test. Fisher’s exact test with simulated P-values was used to compare
TREM2 genotype distributions between patients with schizophrenia and controls. Linkage dis-
equilibrium (LD), TYROBP haplotypes, genotype distributions, minor allele frequencies, and
Hardy–Weinberg equilibrium (HWE) were determined using HaploView v4.2. Statistical
power was calculated with GPower 3 (http://www.gpower.hhu.de/), and statistical significance
was defined at the 95% confidence level (P = 0.05). The ratio of successful genotyping was over
99%, and we extrapolated the missing values for genotype analysis. Bonferroni corrections
were applied to maintain an overall type I error rate of 0.05, taking multiple comparisons into
account.
Results
TYROBP and TREM2 expression in NHD
The NHD patient homozygous for the TYROBP c.141delG mutation exhibited the lowest level
of TYROBP expression among the study participants, while his parents, heterozygous for the
Table 2. Characteristics of the selected two tagging SNPs in TYROBP and one tagging SNP in TREM2.
No. Gene SNP(major/minor allele) Chromosome Location
1 TYROBP rs8113524 (T/C) 35905035, Chr 19 intron
2 TYROBP rs3817624 (C/T) 36398899, Chr 19 intron
3 TREM2 rs2234256 (T/C) 41126655, Chr 6 ex4 (L211P)
doi:10.1371/journal.pone.0136835.t002
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mutation, showed no difference from other groups. In contrast, TREM2 was expressed in the
NHD patient and his parents at the same levels as that in control subjects.
TYROBP and TREM2 expression in AD and schizophrenia
Fig 1 shows TYROBP and TREM2 expression in leukocytes of patients with AD or schizophre-
nia and their controls. TYROBP expression in patients with AD and schizophrenia was similar
to that in their respective control groups (P = 0.44 and P = 0.13, respectively). In contrast,
TREM2 expression was significantly higher in patients with AD and schizophrenia compared
to that in their respective controls (P< 0.001 in both cases). This was also confirmed after Bon-
ferroni corrections. There was no correlation between TREM2 expression and other clinical
variables such as age (r = 0.08, P = 0.71), MMSE (r = 0.01, P = 0.95) in AD, and disease dura-
tion (r = 0.28, P = 0.19) in schizophrenia.
TREM2 expression in AD with APOE ε4
AD patients were typed for the APOE ε4 allele (Table 3). There were no differences in age, sex,
MMSE score, or CDR between the 14 participants (all were ε3/ ε4) in the APOE ε4-positive
AD group [ε4(+) AD] and the 12 participants (all were ε3/ ε3) in the APOE ε4-negative AD
group [ε4(−) AD]. In the AD control group (n = 26), only 2 subjects were positive for the
APOE ε4 allele. For these 3 groups, TYROBP and TREM2mRNA expression levels in leuko-
cytes are shown in Fig 2. In ε4(+) AD, TREM2 expression was significantly higher than that in
AD-cnt (P< 0.001). Although there were no significant differences between ε4(+) and ε4(−)
AD (P = 0.07) or between ε4(−) AD and AD-cnt (P = 0.07), the relative expression of both
genes tended to decrease across groups, in the order ε4(+) AD, ε4(−)AD, and AD-cnt.
Case–control association studies in schizophrenia
We performed genotyping of 3 tag SNPs (rs8113524 and rs3817624 in TYROBP and rs2234256
in TREM2) in 796 patients with schizophrenia and 510 controls (unrelated Japanese partici-
pants). The results are shown in Table 4. The result of haplotype analysis between TYROBP
and schizophrenia is shown in Table 5. In schizophrenia, rs8113524 was not in HWE; however,
rs3817624 and rs2234256 were in HWE. No associations between either TYROBP or TREM2
and schizophrenia were revealed by single marker or haplotype analyses.
Discussion
In NHD, the TREM2/TYROBP signaling pathway is damaged by the mutations in either TYR-
OBP or TREM2, and this has been suggested to cause defects in microglial activity [18]. It is
reported that TYROBP expression is normal in the brain of NHD individuals with the TREM2
mutation [2] and that TREM2mRNA extracted from leukocytes is severely reduced in NHD
individuals with this mutation [19]. Our results, showing decreased levels of TYROBPmRNA
and normal levels of TREM2mRNA in leukocytes of an NHD patient with the TYROBPmuta-
tion, are consistent with previous reports.
In the present study, we found that TREM2 was more highly expressed in leukocytes of
patients with AD and schizophrenia, which were of different disease and age groups, whereas
TYROBP expression was not altered in these groups. Our results may be consistent with the
previous study that revealed TREM2mRNA expression in monocytes was elevated in AD [16].
In the brain, TREM2 is primarily expressed in microglia; however, absent or expressed at low
levels in granulocytes, monocytes, and macrophages [20]. Kiialainen et al. [21] reported that
the microglial expression of Trem2 was high in cultured mouse neuronal cells. The product of
TREM2 Expression in Schizophrenia
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Fig 1. Expression of TYOBP (1A) and TREM2 (1B) in each group. TYROBP expression was the lowest in
the NHD patient and showed no difference in other groups.TREM2 expression was higher in schizophrenic
and AD patients than in the respective controls. P < 0.01 is indicated by ** when the P values were calculated
by Mann–Whitney U-test.
doi:10.1371/journal.pone.0136835.g001
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TREM2 is highly expressed in microglia of the AD brain [10], and Trem2 expression is particu-
larly high in the amyloid plaques of AD model mice [22]. Higher TREM2mRNA levels in
APOE ε4-positive individuals may suggests that TREM2 expression in leukocytes reflects the
AD pathology. Although, unexpectedly, we found no differences between the ε4(+) AD and ε4
(−) AD groups or between the ε4(−) AD and AD-cnt groups, it is possible that this is a false-
negative result and that differences in expression may be confirmed by increasing the number
of subjects.
Hu et al. [16] reported that TREM2mRNA and protein levels were significantly higher in
monocytes of AD and that the expression was inversely associated with the MMSE score.
TREM2mRNA was significantly increased in leukocytes of AD in the present study, and we
found the tendency to inverse correlation between TREM2mRNA expression in leukocytes
and the MMSE score in APOE ε4-negative AD patients (P = 0.08, r = −0.53). We suggest that
elevated TREM2 expression in leukocytes can be utilized as a novel biological marker for AD
and may associate with severity in APOE ε4-negative AD patients.
Surprisingly, TREM2mRNA expression was also elevated in patients with schizophrenia.
To date, this is the first report showing TREM2 upregulation in schizophrenia. Although
schizophrenia has been thought of as a non-neurodegenerative disorder, the evidence from sev-
eral recent reports suggests that schizophrenia may actually be neurodegenerative [23]. Com-
pared to brain tissues, TREM2 is highly expressed in microglia [24] and reduced microglial
activity is reported in Trem2-deficient mice [25]. Although we did not examine inflammatory
markers such as C-reactive protein and IL-6, it is well known that C-reactive protein [26, 27]
and IL-6 [28] are elevated in schizophrenic patients who are free of overt inflammation. Inter-
estingly, increased microglial activity in schizophrenia was also confirmed by both electron
microscopy [29] and positron emission tomography [30]. Higher TREM2mRNA levels in leu-
kocytes of schizophrenia may be associated with peripheral inflammation or microglial
involvement. Because inflammation in glial cells may lead to neuronal changes in schizophre-
nia [31], TREM2 expression in brain samples of patients with schizophrenia should be studied
in the future.
TYROBP expression was not changed in either AD or schizophrenia. TREM2 in extracellu-
lar regions acts as a receptor to bind the ligand [32], whereas TYROBP is present as a second
transmembrane receptor and transmits signal [33]. The difference in the role of each domain
in TYROBP/TREM2 signaling may explain the different expression patterns between TYROBP
and TREM2 in leukocytes. Further studies of the TREM2/TYROBP signaling should be per-
formed to elucidate its role in neurological and psychiatric diseases.
We could not find significant association between TYROBP and TREM2 gene polymor-
phisms and schizophrenia. In addition, the allele rs8113524 was not present in HWE in
schizophrenic patients; this may be due to small population size and low allele frequency [34].
Recently, an association study of 2190 Japanese patients with late-onset AD revealed that
Table 3. Characteristics of APOE ε4 positive and negative group in AD.
ε4-positive (n = 14) ε4-negative (n = 12) P-value
sex (male: female) 5:09 3:09 0.68
age(years mean ± SD) 80.1 ± 4.3 78.9 ± 3.7 0.45
MMSE score (points mean ± SD) 17.7± 7.1 18.2 ± 3.6 0.84
CDR number of each grade (0: 0.5: 1: 2: 3) 0: 0: 5: 7: 2 0: 1: 3: 7: 1 0.64
AD, Alzheimer’s Disease; MMSE, Mini Mental State Examination; CDR, Clinical Dementia Rating. The score of 0–3 shows classification of dementia
(0 = none, 0.5 = questionable, 1 = mild, 2 = moderate, 3 = severe). The P-value was calculated by Student t test, Chi-squired test, and Fisher’s exact test.
doi:10.1371/journal.pone.0136835.t003
TREM2 Expression in Schizophrenia
PLOS ONE | DOI:10.1371/journal.pone.0136835 September 2, 2015 7 / 11
Fig 2. Expression of TYOBP (2A) and TREM2 (2B) in APOE ε4-positive AD [ε4(+) AD], APOE
ε4-negative AD [ε4(−) AD], and AD-cnt groups. TYROBP expression showed no difference. TREM2
expression was significantly higher in ε4-positive AD group than in AD-cnt (including 2 ε4-positive subjects)
group. The expression levels tended to decline in the following order: ε4(+) AD, ε4(−) AD, and AD-cnt.
P < 0.001 after Bonferroni correction is indicated by * *when the P values were calculated by Mann–Whitney
U-test.
doi:10.1371/journal.pone.0136835.g002
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TREM2 variants, including R47H and L211P, were not associated with the disease [35]. There-
fore, higher level of TREM2mRNA in AD and schizophrenia in this study may not be caused
by gene polymorphisms but by other factors such as epigenetic modification.
Our study has several limitations that should be considered. All patients with schizophrenia
were taking antipsychotics and all patients with AD were taking cholinesterase inhibitors at the
time of the blood sampling. Although our NHD patient was also taking antipsychotics and his
TREM2mRNA levels were similar to those of controls, we could not exclude the possibility
that these pharmacological treatments affected the expression of both genes. Influences of food
or physical condition (e.g., body mass index, smoking, infection, and inflammation) on gene
expression in leukocytes were not examined. Moreover, it remains to be confirmed whether
TREM2 expression in the brain is in good agreement with that in leukocytes. In addition, future
studies should assess the correlation between the severity of inflammation or its markers in
central spinal fluid (such as neopterin) and expression of the 2 genes.
In conclusion, we report for the first time that TREM2 expression in leukocytes is elevated
not only in AD but also in schizophrenia and may be a clinical biomarker for these diseases.
We believe that our study is an important first step in understanding the role of TREM2 in the
pathophysiology of AD and schizophrenia.
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controls 2/90/407 0.29 0.095
2 rs3817624 cases 1/59/734 1 0.038 0.86
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